前沿速览047期| CAR-T治B淋 前沿览新知
01
基于单细胞RNA测序比较患者使用的不同CAR-T细胞产品：Axicabtagene Ciloleucel vs. Tisagenlecleucel
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
第一作者：Yu X
J Immunother Cancer (IF=10.6). 2025 Jul 28;13(7):e011807.
全文网址：https://jitc.bmj.com/lookup/pmidlookup?view=long&pmid=40730421
02
CAR-T治疗后的微小残留病灶检测对大B细胞淋巴瘤疗效的预测价值
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell Lymphoma
第一作者：Krasnow N
Blood Adv (IF=7.1). 2025 Jul 24:bloodadvances.2024015788.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024015788/546350/Measurable-Residual-Disease-Detection-after-CAR-T
03
Brexucabtagene Autoleucel治疗复发/难治性套细胞淋巴瘤的真实世界结局：一项CIBMTR分析
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
第一作者：Ahmed N
Blood Adv (IF=7.1). 2025 Jul 24:bloodadvances.2024015014.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024015014/546349/Real-world-outcomes-of-brexucabtagene-autoleucel
04
抗CD19 CAR-T细胞治疗B细胞非霍奇金淋巴瘤及慢性淋巴细胞白血病的生存结局：10年随访研究
Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up
第一作者：Gavrilova T
Blood Adv (IF=7.1). 2025 Jul 21:bloodadvances.2025016504.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016504/546293/Survival-after-anti-CD19-CAR-T-cell-therapy-for-B
05
CAR-HEMATOTOX评分在复发/难治性大B细胞淋巴瘤CAR-T治疗中的血液毒性、感染及生存预测：基于人群的外部验证
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL
第一作者：de Boer JW
Blood Adv (IF=7.1). 2025 Jul 16:bloodadvances.2025016689.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016689/546205/Population-based-validation-of-the-CAR-HEMATOTOX
06
同种异体CAR工程化细胞疗法治疗复发/难治性大B细胞淋巴瘤：一项系统评价与荟萃分析
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
第一作者：Biederstädt A
Front Immunol (IF=5.9). 2025 Jul 8;16:1585556.
全文网址：https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1585556/full
07
伴自身免疫病的侵袭性淋巴瘤患者接受CAR-T细胞治疗的真实世界结局
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART
第一作者：Altomare NJ
Cancers (Basel) (IF=4.4). 2025 Jul 16;17(14):2358.
全文网址：https://www.mdpi.com/2072-6694/17/14/2358
08
2018-2023年社会脆弱性指数与CAR-T细胞治疗实施的相关性分析
Association of Social Vulnerability Index and Chimeric Antigen Receptor T-Cell Therapy Administration, 2018-2023
第一作者：Boloori A
Oncologist (IF=4.2). 2025 Jul 24:oyaf236.
全文网址：https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyaf236/8211682?login=false
09
CAR-T细胞治疗失败并接受双特异性抗体治疗后的异基因造血干细胞移植：可行性、安全性及生存结局
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
第一作者：Barone A
Br J Haematol (IF=3.8). 2025 Jul 22.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.70010
10
Anbalcabtagene Autoleucel与Tisagenlecleucel治疗复发/难治性弥漫大B细胞淋巴瘤的疗效比较
Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
第一作者：Seo HJ
Cancer Res Treat (IF=3.8). 2025 Jul 11.
全文网址：https://www.e-crt.org/journal/view.php?number=3802#:~:text=Conclusion%20Anbal-cel%20showed%20superior%20effectiveness%20over%20tisa-cel%2C%20with,for%20imbalances%20in%20prognostic%20factors%20at%20trial%20enrollment.
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.8-1 valid until 2027.8
供稿与审核：临床开发与医学部